Literature DB >> 8626947

A randomized trial of low osmolar ionic versus nonionic contrast media in patients with myocardial infarction or unstable angina undergoing percutaneous transluminal coronary angioplasty.

C L Grines1, T L Schreiber, V Savas, D E Jones, F J Zidar, V Gangadharan, M Brodsky, R Levin, R Safian, S Puchrowicz-Ochocki, M D Castellani, W W O'Neill.   

Abstract

OBJECTIVES: The purpose of this study was to determine prospectively whether the differences in anticoagulant and antiplatelet effects of ionic and nonionic contrast media after angiographic or clinical outcomes in patients with unstable ischemic syndromes undergoing percutaneous transluminal coronary angioplasty.
BACKGROUND: The interaction of platelets and thrombin with the endothelium of injured vessels contributes to thrombosis and restenosis after coronary angioplasty. Case reports and retrospective observations have reported an increased risk of thrombosis with the use of nonionic contrast media.
METHODS: A total of 211 patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty were randomized to receive nonionic or ionic low osmolar contrast media. Coronary angiograms were assessed by a technician blinded to the study contrast media, and clinical events were monitored by an independent nurse for 1 month.
RESULTS: Patients receiving the ionic media were significantly less likely to experience decreased blood flow during the procedure (8.1% vs. 17.8%, p = 0.04). After the angioplasty, residual stenosis, vessel patency, the incidence of moderate to large thrombi and use of adjunctive thrombolytic therapy were similar between the two groups. However, patients receiving ionic media had fewer recurrent ischemic events requiring repeat catheterization (3.0% vs. 11.4%, p = 0.02) and repeat angioplasty during the initial hospital stay (1.0% vs. 5.8%, p = 0.06). One month after angioplasty, patients receiving ionic contrast media reported significantly fewer symptoms of any angina (8.5 vs. 20.0%, p = 0.04) or of angina at rest (1.4% vs. 11.8%, p = 0.01) and a reduced need for subsequent bypass surgery (0% vs. 5.9%, p = 0.04), compared with patients receiving the nonionic media.
CONCLUSIONS: These findings demonstrate that in patients with unstable ischemic syndromes undergoing coronary angioplasty, the use of ionic low osmolar contrast media reduces the risk of ischemic complications acutely and at 1 month after the procedure. Therefore, low osmolar ionic contrast media should be strongly considered when performing interventions in patients with unstable angina or myocardial infarction.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8626947     DOI: 10.1016/0735-1097(96)00040-x

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  6 in total

Review 1.  Effects of iodinated contrast media on blood and endothelium.

Authors:  Peter Aspelin; Fulvio Stacul; Henrik S Thomsen; Sameh K Morcos; Aart J van der Molen
Journal:  Eur Radiol       Date:  2006-01-05       Impact factor: 5.315

Review 2.  [Optimal x-ray contrast media for ambulatory coronary angiography from the microcirculatory point of view].

Authors:  R Bach; F Jung
Journal:  Herz       Date:  1998-02       Impact factor: 1.443

3.  An analysis of mechanisms underlying the antifibrinolytic properties of radiographic contrast agents.

Authors:  P M Farrehi; Y Zhu; W P Fay
Journal:  J Thromb Thrombolysis       Date:  2001-12       Impact factor: 2.300

Review 4.  Comparative tolerability of contrast media used for coronary interventions.

Authors:  Enrique Esplugas; Angel Cequier; Joan A Gomez-Hospital; Bruno García Del Blanco; Francisco Jara
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 5.  Thrombolytics: drug interactions of clinical significance.

Authors:  S Harder; U Klinkhardt
Journal:  Drug Saf       Date:  2000-11       Impact factor: 5.606

6.  Influence of ionic and non-ionic radiographic contrast media on leukocyte adhesion molecules.

Authors:  Guy L J Vermeiren; Roel Willems; Marc J Claeys; Chris Vrints; Herman Slegers; Philippe G Jorens
Journal:  Mediators Inflamm       Date:  2003-10       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.